Clinical Trial Update: A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

View source ↗

Summary

A pediatric clinical trial evaluating safety and effectiveness of Pradaxa pellets (dabigatran etexilate) for venous thromboembolism in children aged 3 months to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa Pellets (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism | Status: TERMINATED